Time for a buyout After Jan's spectacular results, many were seeing $5 sp by June. After seeing the lack of progression on many fronts, this becoming increasingly unlikely.
The announcement of Sam Wiseman to SAB is interesting news, but as indicated by market reaction, not compelling from a business perspective.
Many of us are questioning management decisions, are disappointed in BoD. Let's face it, Dr. T is not Elon Musk or Steve Jobs.
The company is late on some key milestones (Q1 to complete diabetes study enrollment).
We make assumptions to fill the void of missing information. We do not see the game plan of when this company will start generating revenue in an automous fashion without further share dilution.
This could all easily be solved with a buyout. Until then, or a very lucrative collaboration with major pharma, we will continue to vegetate in the $1.50 range.
For those tempted to say This post is irrational, there are 5 peer companies with valuations at 4x that say otherwise.